Pregnyl Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to growing use of hcg in fertility protocols, expansion of ivf and art clinics, established role in male hypogonadism treatment, increasing clinical expertise in hormone therapy, availability of injectable fertility drugs.

The growth in the forecast period can be attributed to rising infertility prevalence, increasing demand for assisted reproduction, expansion of fertility treatment access, growing male fertility awareness, increasing adoption of personalized hormone regimens. Major trends in the forecast period include increasing demand for fertility hormone therapies, rising use in assisted reproductive techniques, growing focus on male fertility treatments, expansion of injectable hormone applications, enhanced emphasis on controlled hormone administration.

The expansion of healthcare infrastructure is expected to drive the growth of the Pregnyl market in the future. Healthcare infrastructure refers to the physical and organizational structures, facilities, resources, and systems needed to deliver healthcare services to the population. This expansion is influenced by several key factors, including the aging global population, the rise in chronic diseases, and technological advancements. A strong healthcare infrastructure supports the growth of Pregnyl by ensuring access to fertility treatments, proper storage and administration facilities, and trained healthcare professionals. For example, in January 2024, the American Hospital Association, a US-based professional organization, reported that the United States had 6,120 hospitals with a total of 916,752 staffed beds and 33,679,935 total admissions across all facilities in 2024. Additionally, a report by the Office for National Statistics, a UK-based government agency, published in May 2024, showed that total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022. As a result, the ongoing expansion of healthcare infrastructure is driving the growth of the Pregnyl market.

The rising rates of infertility are expected to drive the growth of the Pregnyl market in the future. Infertility is defined as the inability to achieve a pregnancy after 12 months or more of regular unprotected sexual intercourse. The increasing prevalence of infertility is linked to more couples delaying childbearing into their late 30s, a period when fertility naturally declines. Pregnyl plays a crucial role in addressing infertility by supporting assisted reproductive techniques, such as triggering ovulation or supporting the luteal phase. For example, in April 2023, the World Health Organization (WHO), a Switzerland-based intergovernmental organization and specialized agency of the United Nations, reported that approximately 17.5% of the adult population, or about 1 in 6 people worldwide, experience infertility in their lifetime, challenging previous assumptions about regional disparities. As a result, the rising infertility rates are expected to drive continued growth in the Pregnyl market.

In July 2025, Organon & Co., a U.S.-based pharmaceutical company, acquired Merck & Co., Inc.'s biotech manufacturing site at De Geer in Oss for an undisclosed sum. This acquisition allowed Organon to enhance its fertility drug manufacturing capabilities and secure a supply of active ingredients for its fertility portfolio, including hCG-based products like Pregnyl. Merck & Co., Inc. is a Germany-based pharmaceutical company known for its innovative medicines, vaccines, and healthcare solutions across major therapeutic areas.

Major companies operating in the pregnyl market are Merck & Co.Inc.

North America was the largest region in the pregnyl market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pregnyl market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pregnyl market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the pregnyl market by increasing costs of imported hormone synthesis materials, sterile injectable manufacturing equipment, vial and syringe components, and cold-chain transportation services. Europe and North America are most affected due to reliance on specialized pharmaceutical imports, while emerging markets face higher procurement costs. These tariffs are raising treatment expenses and affecting clinic procurement decisions. However, they are also encouraging local injectable manufacturing, regional packaging operations, and improved supply resilience for fertility hormone products.

The pregnyl market research report is one of a series of new reports that provides pregnyl market statistics, including pregnyl industry global market size, regional shares, competitors with a pregnyl market share, detailed pregnyl market segments, market trends and opportunities, and any further data you may need to thrive in the pregnyl industry. This pregnyl market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pregnyl is a medication that contains the hormone human chorionic gonadotropin (hCG) and is utilized for various medical purposes. It is commonly prescribed to stimulate ovulation in women undergoing fertility treatments, enhance male fertility by increasing testosterone levels and sperm production, and treat undescended testicles in boys. Pregnyl is administered through injection and should always be used under medical supervision.

The main indications for Pregnyl include fertility treatments for women, male infertility, and hypogonadotropic hypogonadism. In women, it is primarily used to stimulate ovulation in those facing difficulties conceiving due to conditions such as polycystic ovary syndrome (PCOS) or other ovulatory disorders. Pregnyl contains human chorionic gonadotropin (hCG), which mimics the natural hormone that triggers ovulation. It is available through various distribution channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and is commonly used by fertility clinics, research institutions, and other healthcare providers.

The pregnyl market consists of sales of pregnyl injections, hCG-based injections, and specialized hCG vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.